PLASMA CELL LEUKEMIA
Clinical trials for PLASMA CELL LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new PLASMA CELL LEUKEMIA trials appear
Sign up with your email to follow new studies for PLASMA CELL LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug may reduce dangerous side effects of stem cell transplants in older patients
Disease control OngoingThis early-phase study tests whether the drug itacitinib can prevent cytokine release syndrome (a severe inflammatory reaction) and reduce the need for other immune-suppressing medicines after a stem cell transplant in people aged 60 and older with certain blood cancers. Particip…
Matched conditions: PLASMA CELL LEUKEMIA
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 05, 2026 12:06 UTC
-
Cancer drug dose study canceled before it began
Knowledge-focused TerminatedThis study was designed to find the safest and most effective dose of the chemotherapy drug bendamustine for people with multiple myeloma that had not been cured by earlier treatments. It was a Phase 1 trial, meaning it focused on side effects and dosing, not on curing the diseas…
Matched conditions: PLASMA CELL LEUKEMIA
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Knowledge-focused
Last updated Jun 22, 2026 12:08 UTC
-
Lab tests could pick the right drug for tough myeloma cases
Knowledge-focused OngoingThis study tests a new way to choose treatments for people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to standard therapy. Researchers use a lab test that checks many drugs at once, along with genetic information, to find which drug or d…
Matched conditions: PLASMA CELL LEUKEMIA
Phase: NA • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:03 UTC